Skip to main content

Engimmune Therapeutics banks 15.5 million Swiss francs

| News

Engimmune Therapeutics banks 15.5 million Swiss francs


Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies against cancer after receiving seed financing to the tune of 15.5 million Swiss francs. The company was founded and built up with the help of the biotech accelerator and incubator BaseLaunch.


Engimmune Therapeutics has received investments totaling 15.5 million Swiss francs for the development of novel T-cell receptor (TCR) therapeutics to combat cancer. The Basel-based biotech firm is a spin-off from the Department for Biosystems Science and Engineering (D-BSSE), likewise based in Basel, of the Swiss Federal Institute of Technology in Zurich (ETH). The company was incubated and initially financed via BaseLaunch, an incubator and accelerator operated by the investment and innovation promotion agency Basel Area Business & Innovation.

The seed financing round that has now closed was led by the Swiss venture capital fund Pureos Bioventures, a BaseLaunch partner, and Novo Seeds, the early-stage investment and company creation team of the Danish firm Novo Holdings. The gross proceeds from this financing round are, according to a press release, to be put towards further expanding the Engimmune pipeline, bolstering the research team in Switzerland and gaining a foothold in the Danish market.

Long-standing support from BaseLaunch

Engimmune has also announced the appointment of TCR pioneer and industry veteran Dr. Bent Jakobsen as Chairman of the Board. As part of the transaction, Dominik Escher and Jørgen Søberg Petersen will join the company as Board Directors, while Ximing Ding and João Ribas will join as observers.

“The long-standing support from BaseLaunch together with these industry-leading investors and the in-depth expertise of Bent gives Engimmune the standing to become a leading contributor to this competitive yet promising space”, explains Søren Mouritsen, CEO of Engimmune, in the press release.

“It was a real privilege to work alongside the team at Engimmune to help build the company from scratch”, comments Stephan Emmerth, BaseLaunch Director, in the press release.  This group of investors will enable the company “to continue developing their pioneering technology platforms to deliver truly differentiated TCR therapeutics”, he adds.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.